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ABSTRACT
Inhibitors of mitochondrial respiration and ATP synthesis may promote the selective
killing of respiration-competent cancer cells that are critical for tumor progression.
We previously reported that CADD522, a small molecule inhibitor of the RUNX2
transcription factor, has potential for breast cancer treatment. In the current study,
we show that CADD522 inhibits mitochondrial oxidative phosphorylation by decreasing
the mitochondrial oxygen consumption rate (OCR) and ATP production in human breast
cancer cells in a RUNX2-independent manner. The enzyme activity of mitochondrial
ATP synthase was inhibited by CADD522 treatment. Importantly, results from cellular
thermal shift assays that detect drug-induced protein stabilization revealed that CADD522
interacts with both α and β subunits of the F1-ATP synthase complex. Differential scanning
fluorimetry also demonstrated interaction of α subunits of the F1-ATP synthase to
CADD522. These results suggest that CADD522 might target the enzymatic F1 subunits in
the ATP synthase complex. CADD522 increased the levels of intracellular reactive oxygen
species (ROS), which was prevented by MitoQ, a mitochondria-targeted antioxidant,
suggesting that cancer cells exposed to CADD522 may elevate ROS from mitochondria.
CADD522-increased mitochondrial ROS levels were enhanced by exogenously added
pro-oxidants such as hydrogen peroxide or tert-butyl hydroperoxide. Conversely,
CADD522-mediated cell growth inhibition was blocked by N-acetyl-l-cysteine, a general
ROS scavenger. Therefore, CADD522 may exert its antitumor activity by increasing
mitochondrial driven cellular ROS levels. Collectively, our data suggest in vitro proof-ofconcept that supports inhibition of mitochondrial ATP synthase and ROS generation as
contributors to the effectiveness of CADD522 in suppression of tumor growth.

INTRODUCTION

patient survival. Despite recent advances in treatment,
however, its clinical management still remains a challenge
[1]. Therefore, development of new strategies that increase
the therapeutic index of chemotherapeutics and decrease
the incidence of the disease are needed. Chemotherapy,

Breast cancer (BC) is the second leading cause of
cancer-related deaths among women, but early detection
and improved treatment options have led to increased
www.oncotarget.com
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radiation and hormonal therapy are useful in treating
advanced BC [2], however, targeting cancer metabolism
has become an attractive therapeutic option [3–6].
Alterations of mitochondrial function are associated
with development of several types of cancer [7]. In contrast
to Warburg’s first observations, maintaining functional
mitochondria appears to be key for cancer cell survival
and proliferation [8]. Mitochondria are still functional in
glycolytic cancer cells (with high Glut-1 and phosphoAkt expression) producing abundant amounts of ATP [9].
Recent reports suggest that inhibitors of mitochondrial
oxidative phosphorylation (OXPHOS) could promote the
selective eradication of stem-like tumor cells due to their
preferential sensitivity to mitochondrial reactive oxygen
species (ROS) [10]. Functional mitochondria that are
respiration competent are thus critical for tumorigenesis
and targeting mitochondrial metabolism may be a novel
and successful therapeutic strategy for cancer [7].
Under physiological conditions, mitochondrial
membrane proton pumps (i.e., electron transport chain,
ETC) generate an electrochemical proton gradient, the
main component of which is mitochondrial membrane
potential (MMP, ∆Ψm). ATP synthase acts as a sensor of
glucose supply by utilizing a proton gradient generated
by the ETC from electron donors that ultimately originate
from glucose-derived pyruvate. The protonmotive force
(∆p) is used by ATP synthase to produce ATP to meet
the energy needs of the cell. Reactive oxygen species
(ROS) are primarily generated from complex I and III in
mitochondria, but increased ROS is often due to blockade
of complex IV [11, 12] or ATP synthase [13–15]. ATP
synthase inhibition results in ∆Ψm elevation, leading to
increased electron leak to superoxide [15]. Mitochondrial
ROS are important for cell proliferation and tumor growth
[16], but also can induce DNA damage, protein oxidation
and lipid peroxidation [15, 17], potentially initiating
cell death [18, 19]. Intrinsic MMP (∆Ψm) in cancer
cells generally correlates with tumor development and
progression, and invasive cellular behavior [20].
Numerous molecules that act on mitochondria are
currently used or being tested in clinical trials [21], and
many therapeutics that target mitochondria reduce ATP
levels and increase ROS production [15, 22–28]. For
example, tamoxifen is widely used in adjuvant therapy
for all stages of BC. It inhibits complexes III and IV,
inducing MMP (∆Ψm) collapse [29] and increased ROS
production [30]. In addition, it has been reported that
the mitochondrial Fo/F1-ATP synthase is a target for
dietary phytochemicals such as resveratrol, genistein,
and epigallocatechin [14], which can reduce ATP levels.
Resveratrol targets Complexes I and II, but it also targets
the F1 domain of ATP synthase, resulting in a noncompetitive inhibition of F1-ATP synthase activity [31].
Therefore, inhibiting mitochondria may be a rational
therapeutic approach, since BC cells are especially
sensitive to ROS-mediated oxidative stress [23].
www.oncotarget.com

ATP synthase is reported to be upregulated in
breast tumors. Among five subunits in the hydrophilic
F1-portion of the mitochondrial H+-ATP synthase, the α
subunits are correlated with larger, poorly differentiated
and high stage tumors [32, 33]. However, one report
suggests no significant difference in the expression levels
of β-F1-ATP synthase in BC tissues when compared with
normal breast [34]. Nonetheless, reduced expression of the
catalytic β subunit (β-F1-ATP synthase) is linked to cancer
progression [35–37] and resistance of cancer cells to
standard anticancer therapies [38–41]. β-F1-ATP synthase
levels are also inversely correlated with aerobic glycolysis
in cancer cells [42].
Most ATP synthase inhibitors often demonstrate
unacceptable in vivo toxicity [43]. However, some of them
still have potential to be used as anticancer agents. For
example, oligomycin A inhibits the proton-translocating
Fo-portion of the ATP synthase, and also affects the
F1-portion at high concentration [44, 45]. Oligomycin
dramatically attenuates BC metastatic seeding in the
lungs, which demonstrates the functional importance of
OXPHOS in metastasis and highlights its potential as a
therapeutic target to prevent metastatic spread in patients
with BC [46]. Aurovertin B inhibits the activity of ATP
synthase by interacting with the β subunit of the F1ATP synthase and limits proliferation of BC cells with
little influence on the normal mammary epithelial cells
(MCF-10A) [32]. Citreoviridin, which is in the same
class as aurovertin, targets the β subunit of the F1-ATP
synthase [47, 48], inhibits the growth and proliferation
of BC cells as well as lung adenocarcinoma cells [49,
50]. Rhodamine123 inhibits BC colony formation, which
was reported to be due to inhibition of the FoF1-ATP
synthase enzyme complex leading to ATP depletion [51].
Benzodiazepine (Bz-423) directly inhibits the F1-ATP
synthase and initiates apoptosis by increasing generation
of superoxide (O2–) from the respiratory chain within
mitochondria [43].
We previously reported that the transcription
factor runt-related transcription factor 2 (RUNX2)
promotes glycolytic switching in BC cells by increasing
expression of genes regulating glycolytic pathways
[52]. RUNX2 decreases pyruvate dehydrogenase (PDH)
activity but RUNX2 KD increases mitochondrial oxygen
consumption rate (OCR) by increasing the activity of
PDH, a rate limiting step for entry into the TCA cycle
at the branch point for pyruvate utilization. These
findings led us to hypothesize that targeting RUNX2
might inhibit BC growth and/or progression by reversing
tumor cell dependence on glycolysis. In our effort to find
small molecules that target RUNX2 by interfering with
RUNX2 binding to the specific DNA sequences, we used
Computer-Assisted Drug Design (CADD) [52, 53]. Based
on this approach, CADD522 (Supplementary Figure 2,
left) was identified as a potent inhibitor of RUNX2-DNA
binding [52, 53].
3864
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CADD522 inhibited the in vitro DNA binding
activity of RUNX2 at nanomolar concentrations (IC50
≅ 10 nM) [53] and inhibited BC growth and metastasis
in both in vitro and in vivo models by specifically
downregulating RUNX2-mediated transcription of
downstream targets [52]. Since CADD522 suppressed
RUNX2-mediated Glut-1 expression as well as glucose
uptake and utilization [52], we initially hypothesized that
CADD522 could restore the mitochondrial metabolic
pathways that RUNX2 repressed. Unexpectedly,
however, we observed that CADD522 directly targeted
mitochondrial oxidative phosphorylation, decreasing
mitochondrial OCR and ATP production in BC cells.
CADD522 repressed FoF1-ATP synthase activity but
increased ROS levels in a RUNX2-independent manner.
Therefore, CADD522 may demonstrate therapeutic
potential for BC by targeting mitochondria.

CADD522 at the time of assay. Increasing concentrations
of CADD522 (0~200 µM) were directly injected into
port A of the XF analyzer. In parallel, oligomycin A
was injected in separate wells as a positive control.
Unexpectedly, CADD522 reduced the respiratory capacity
of both T47D-Empty and T47D-RUNX2 cells in a
concentration-dependent manner (Figure 1A). Oligomycin
A had no significant influence on the FCCP-induced
maximal respiratory capacity (MRC) compared to the
vehicle control (Control, 0.1% DMSO).
Next, we treated cells with CADD522 (50 µM) for
72 hr and determined the OCR without further addition
of CADD522 during the assay. Mitochondrial respiration
parameters-baseline OCR (BL), maximal respiratory
capacity (MRC), reserve capacity (RC), ATP productionlinked OCR (AP), and proton leak-linked OCR (PL)
(Supplementary Figure 2A, right) were measured by
the addition of mitochondrial OXPHOS inhibitors such
as oligomycin A (O) or antimycin A (AA) [55]. Among
the mitochondrial respiration parameters, CADD522mediated inhibition was mostly observed in the MRC, RC
and AP (Figure 1B and 1C). The percent (%) inhibition
of MRC and RC was more profound in MCF7-RUNX2
cells than MCF7-Empty cells, which was also in a timedependent manner (Supplementary Figure 2B). Similar
results were observed in cells treated with CADD522 for
less than 30 hr (Supplementary Figure 2C and 2D). These
results indicate that CADD522 significantly inhibits OCR
in both ectopic RUNX2-expressing T47D and MCF7 cells
as well as their Empty controls. Mean values of OCR and
% inhibition of individual parameters are summarized in
Supplementary Table 1.
To exclude the possibility that long-term use of
G418 for selection and maintenance of stable cell lines
might affect cellular OCR response to CADD522, we
determined OCR in MDA-468 and MCF7 cells after
exposure to CADD522 in the absence of G418. The OCR
was determined in the absence of CADD522 at the time of
analysis. CADD522 treatment for 6 hr in MDA-468 cells
(Figure 2A) or MCF7 cells (Supplementary Figure 3A)
did not have dramatic effects on the OCR compared to
the vehicle control, whereas 24 hr of CADD522 treatment
significantly suppressed the mitochondrial respiration
parameters in MDA-468 cells (Figure 2A–2C). The
percent (%) Inhibition of MRC and RC increased in a
time-dependent manner (Figure 2B, right).
In addition, CADD522 significantly suppressed
the baseline OCR (BL) of MDA-468 and MCF7 cells
(Figure 2C). In MDA-468 cells, CADD522-mediated
inhibition was greater after 24 hr than after 6 hr despite
no difference between vehicle controls. Inhibition of
the baseline OCR was clearly observed in both T47DEmpty and -RUNX2 cells treated with CADD522 for
72 hr, as well as in MCF7-Empty and -RUNX2 cells
with CADD522 for 30 hr (Supplementary Figure 3B).
However, no significant difference was observed in the

RESULTS
Inhibition of mitochondrial respiration
Mitochondrial respiration is the most important
generator of cellular energy through the process of energy
conversion of carbon substrates into ATP. Previously,
we showed that loss of RUNX2 by gene knockdown
(KD) increases OCR [54]. Our extended studies now
demonstrate that ATP levels and mitochondrial ATP
synthase activity significantly increase in Hs578t cells
after RUNX2 KD compared to non-targeting control
(NTC) (Supplementary Figure 1A and 1B). The increase
was observed in Galactose M, a condition where
cellular ATP production is dependent on mitochondrial
OXPHOS rather than glycolysis, but not in SerumFree Glucose M. Mitochondrial Complex I activity also
increased in RUNX2 KD cells compared to NTC cells
(Supplementary Figure 1C). In contrast to a slight but
significant increase of mitochondrial mass in RUNX2
KD cells (Supplementary Figure 1D), no significant
difference in MMP (∆Ψm) was observed between NTC
and RUNX2 KD cells (Supplementary Figure 1E). In
addition, intracellular and mitochondrial ROS levels
determined by DCF and MitoSox fluorescence intensity,
respectively, as well as the H2O2 Luc intensity increased in
Hs578t cells with RUNX2 KD (Supplementary Figure 1F
and 1G). Collectively, these findings indicate that RUNX2
KD results in activation of mitochondrial ATP synthase
activity, which may lead to increases in respiration [54],
ATP production and ROS generation.
These findings led us to hypothesize that CADD522
(Supplementary Figure 2A, left), a RUNX2-DNA binding
inhibitor, would promote mitochondrial OCR and ATP
synthesis in BC cells expressing RUNX2. To test this
hypothesis in this study, we first determined the kinetics
of the acute (immediate) OCR changes in T47D-Empty
and -RUNX2 overexpressing cells by exposing cells to
www.oncotarget.com
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Decrease in mitochondrial ATP production

non-mitochondrial (antimycin A-resistant) OCR (NM,
value at t = 63 min) between vehicle- and CADD522treated cells (Supplementary Figure 3C and Figure 1C),
indicating that CADD522 targets mitochondria rather
than other cellular sources of respiration. Taken together,
our data clearly show that CADD522 represses the key
mitochondrial respiration parameters. Our previous results
showed that among thirteen BC cells lines tested, MDA468 and MCF7 cells displayed the highest sensitivity to
CADD522 in short- and long-term cell growth assays even
though MDA-468 and MCF7 cells express low levels of
RUNX2 [52]. Therefore, CADD522 may target primarily
mitochondria in BC cells with low levels of RUNX2.

When cells have limited glucose availability, ATP
is synthesized mainly from mitochondria. Cells in culture
medium with pyruvate or galactose but not glucose
are primarily dependent on OXPHOS as glycolysis
contribution to ATP generation is minimized. In contrast,
under serum-free, glucose-supplemented conditions
(Serum-Free Glucose M), normal mitochondrial function
is compromised, and mitochondrial ATP production is
suppressed. Indeed, we observed that BC cells in Pyruvate
M or Galactose M exhibited lower levels of ATP than in
Complete M owing to suppression of ATP production

Figure 1: Inhibitory effect of CADD522 on mitochondrial OCR. (A) Acute OCR changes were determined in T47D-RUNX2

and -Empty cells with no prior CADD522 treatment. Cells seeded in Seahorse plates were incubated overnight in growth medium without
G418, and then replenished with Seahorse-Certified Medium on the assay day. Vehicle control (0.1% DMSO), Oligomycin or CADD522
were directly injected into port A of the XF Extracellular Flux Analyzer, and OCR was measured. Data (% OCR) are presented as the
percentage of the basal OCR value at t = 12 min (100%). Experiments were performed in four replicates and repeated twice (mean ± SD).
O, Oligomycin (1 μg/ml); F, FCCP (1 µM, port B); P, pyruvate (10 mM, port C); AA, antimycin A (1 µM, port D). Red line, maximal OCR
value of the Control at t = 57 min. (B) Cells were treated with CADD522 for 6~72 hr and replenished with Seahorse-Certified Medium
with no CADD522. OCR was measured in the XF Extracellular Flux Analyzer. Data (mean ± SD) are presented as OCR (pMoles/min/µg
protein). (C) Mitochondrial respiratory parameters were calculated as described in Material and Methods: Maximal respiratory capacity
(MRC), mitochondrial reserve capacity (RC), ATP production-linked respiration (AP), proton leak-linked respiration (PL), baseline
respiration (BL), and non-mitochondrial respiration (NM). Experiments were performed in four replicates and data are expressed as mean
± SE from two independent experiments. *P < 0.05 compared to Empty cells with vehicle control (0.1% DMSO); #P < 0.05 compared to
RUNX2-expressing cells with vehicle control.
www.oncotarget.com
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derived from glycolysis and possible changes in energy
demand (Figure 3A, Supplementary Figure 4A).
To examine whether CADD522-induced OCR
changes have a functional effect on ATP levels, we treated
cells with CADD522 for a short period of time (4~6 hr)
and determined changes in ATP levels by bioluminescence
assay. CADD522 significantly inhibited ATP levels
in BC cells, which was greater in cells incubated in
media without glucose (Pyruvate M, Galactose M) than
in complete M (Figure 3A). Consistently, ATP levels
decreased in both ectopic RUNX2-expressing MCF7 and
T47D cells and their Empty controls when glycolytic ATP
generation was blocked (Figure 3B and 3C). However,
CADD522 had little effect on ATP levels when cells were
incubated in Serum-Free Glucose M (Supplementary
Figure 4B), indicating that these cells are sensitive to
CADD522-mediated ATP inhibition primarily under
conditions when they depend on mitochondrial OXPHOS.
Decreased ATP levels in response to CADD522 were
observed when cells were treated with CADD522 for a
relatively long period of time (24~48 hr) (Supplementary
Figure 4C), and also were generally observed in BC cells
regardless of their RUNX2 status.

radicals. Mitochondrial respiration normally restricts
ROS production since electron flow is very efficient, but
suppression of respiration and ATP production result in a
greatly enhanced rate of free radical production [15]. ROS
consist of the oxygen radical superoxide anion (O2•−) and
hydroxyl radical (•OH) and non-radical oxygen species,
such as hydrogen peroxide (H2O2) and singlet oxygen (O2).
To determine whether inhibition of respiration (OCR) by
CADD522 increases intracellular ROS levels, we treated
cells with CADD522 for 6 or 24 hr and incubated cells with
the fluorogenic dye CM-H2DCFDA that measures hydroxyl,
peroxyl, and other ROS within cells [56]. CADD522
significantly increased intracellular ROS production in
both MCF7 and MDA-468 cells (Figure 4A). However, cotreatment with N-acetyl-l-cysteine (NAC, 5 mM), a widely
used antioxidant [57, 58], diminished the CADD522increased intracellular ROS levels to below the level of the
control (Figure 4B). We further determined mitochondrial
ROS levels in cells treated with CADD522 for 24 hr using
MitoSox Red, a fluorescent dye relatively specific for
superoxide. As shown in Figure 4C and 4D, CADD522
increased the level of mitochondrial ROS in MCF7 and
MDA-468 cells, which was more evident in serum-free
than serum-containing condition. Similar results were
observed in CADD522-treated ectopic RUNX2-expressing
T47D and MCF7 cells as well as their Empty controls
(Supplementary Figure 5A and 5B). In addition, CADD522regulated mitochondrial ROS levels were significantly

Increased mitochondrial ROS generation
Mitochondria are a source as well as a target of ROS.
Leakage of electrons from the ETC produces superoxide

Figure 2: Inhibition of mitochondrial OCR in CADD522-treated BC cells. (A) MDA-468 cells were treated with CADD522

for 6 and 24 hr and replenished with Seahorse-Certified Medium with no CADD522. Data (mean ± SD) are presented as OCR (pMoles/
min/µg protein). O, Oligomycin (1 μg/ml); F, FCCP (1 µM, port B); P, pyruvate (10 mM, port C); AA, Antimycin A (1 µM, port D). (B)
Mitochondrial respiration parameters in MDA-468 cells treated with CADD522 for 24 hr (left). Experiments were performed in four
replicates and data are presented as mean ± SE from two independent experiments. *P < 0.05 compared to Control. Percent (%) inhibition
of MRC and RC in MDA-468 cells treated with CADD522 (right). *P < 0.05 compared to % inhibition at 6 hr of treatment. (C) Baseline
cellular OCR (BL) was calculated from basal respiration (value at t = 12 min) after subtracting NM. Experiments were done in four
replicates and repeated twice (mean ± SE). *P < 0.05 compared to Control; #P < 0.05 compared to BL of CADD522-treated cells for 6 hr.
www.oncotarget.com
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reduced by mitochondria-targeted antioxidants MitoQ (5
µM) [59] and MitoTEMPO (MitoT, 50 µM) [60] (Figure
4E). These results indicate that part of ROS levels increased
by CADD522 may be derived from mitochondria.

short treatment time in Galactose M (4 hr) (Figure 5A,
right). These results indicate that reduced ATP synthase
activity persists after CADD522 was removed during
isolation of protein lysates.
To rule out that the inhibition could have been due to
blocking upstream components of the ETC, protein lysates
were prepared from MDA-231 and MDA-468 cells without
prior CADD522 treatment. After immunocapture with
specific antibody, the ATP synthase enzyme was incubated
with CADD522 (0~2 µM) in vitro for 30 min. As seen
in Figure 5D and Supplementary Figure 6C, CADD522
decreased the slope of ATP synthase (i.e., inhibition of
the activity) in either MDA-231 or MDA-468 cells in a
concentration-dependent manner. These results suggest that
lower ATP levels in response to CADD522 could be due to
direct inhibition of the mitochondrial ATP synthase activity.
The mean values of the ATP synthase activity of individual
cells are shown in Supplementary Table 2.

Inhibition of ATP synthase enzymatic activity
OCR is regulated by both ETC complex activity
and the rate of ATP production from mitochondrial H+ATP synthase, a nuclear genome-encoded enzyme that
is a central player in defining the bioenergetic activity
of the cell. To investigate how CADD522 suppresses
the level of ATP, we incubated BC cells in Complete
M with CADD522 (50 µM) for 24 hr, and then isolated
cell lysates to perform quantitative measurement of the
mitochondrial ATP synthase activity. The ATP synthase
enzyme was immunocaptured within the wells of a
microplate and CADD522 was not further added during
the assay. CADD522 significantly inhibited the activity
of ATP synthase in BC cells (Figure 5A, left). Significant
decrease of ATP synthase activity was also observed in
ectopic RUNX2-expressing MCF7 cells treated with
CADD522 for 24 hr (Figure 5B and 5C, Supplementary
Figure 6A). Similar inhibition was observed even after a

No changes in MMP or mitochondrial Complex
I activity
Under physiological conditions, mitochondrial
membrane proton pumps of the ETC generate an

Figure 3: CADD522 treatment suppresses the levels of ATP. (A) Cells were treated with CADD522 (50 µM) in Pyruvate M (4

hr), Galactose M (4 hr) or Complete M (6 hr), and cellular ATP levels were determined. Galactose M, DMEM with 5 mM galactose, 1 mM
pyruvate, no glucose, 2 mM glutamine, 10% serum; Pyruvate M, DMEM with 2 mM pyruvate, no Glucose, no Glutamine with 5% serum.
Complete M, 25 mM glucose, 2 mM glutamine, 1 mM pyruvate, 10% serum. Experiments were done in four replicates and repeated twice
(mean ± SD). *P < 0.05 compared to vehicle control (0.1% DMSO). Red line, ATP level of the control MDA-231 cells in Complete M. (B,
C) Ectopic RUNX2 expressing cells and their Empty controls were treated with CADD522 in Pyruvate M (4 hr) or Galactose M (6 hr), and
cellular ATP levels were determined. *P < 0.05 compared to the vehicle control of Empty cells; #P < 0.05 compared to the vehicle control
of ectopic RUNX2-expressing cells.
www.oncotarget.com
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electrochemical proton gradient, the main component
of which is MMP (∆Ψm). Proton pumping promotes
normal respiratory function and synthesis of ATP to meet
the energy needs of the cell. To determine the effect of
CADD522 on MMP (∆Ψm), we incubated BC cells with a
fluorescent ∆Ψm-sensitive dye, JC-1. However, we did not
observe any significant difference of JC-1 fluorescence
intensity between cells treated with vehicle and CADD522
for 4~72 hr (Supplementary Figure 7A). Changes of JC-1
fluorescence by CADD522 were also not observed in
cells incubated with TMRM, another ∆Ψm-detecting dye.

These results show that CADD522 targets mitochondria
without causing significant collapse of ∆Ψm.
Complex I (NADH dehydrogenase) is the primary
electron acceptor from the TCA cycle metabolite NADH.
A blockade of the terminal OXPHOS step (mitochondrial
ATP synthase) can also feedback to slow complex I
activity, preventing efficient transfer of electrons, and thus
leading to increased ROS [61]. We determined complex
I activity under the same cell conditions described for
measuring mitochondrial ATP synthase activity. However,
complex I activity was not altered by CADD522 treatment

Figure 4: CADD522 increases ROS level. (A, B) Cells were treated with CADD522 (50 µM) for 6 or 24 hr in complete growth

medium, and intracellular ROS levels were determined with fluorescence-based CM-H2DCFDA. pH-adjusted NAC (5 mM, pH 7.2) was
pre-treated for 1 hr and further incubated with CADD522 for 24 hr. Data (DCF fluorescence relative to Calcein green fluorescence) are
presented as Fold, which was calculated from the relative value to the average of the vehicle control (0.1% DMSO, = 1). All determinations
were in four replicates and repeated twice (mean ± SD). *P < 0.05 compared to the control; #P < 0.05 compared to CADD522 alone. (C)
Cells were treated with CADD522 for 24 hr in complete growth medium, and mitochondrial superoxide levels were measured by incubating
cells with MitoSox Red dye. (D) Cells were treated with CADD522 for 3 or 24 hr in serum-free medium (SFM), and mitochondrial
superoxide levels were determined. (E) Mitochondria-specific antioxidants MitoQ (5 µM) and MitoTempo (MitoT, 50 µM) were pretreated for 1 hr and further incubated with CADD522 for 24 hr in serum-free condition.
www.oncotarget.com
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for up to 72 hr in all BC cells examined (Supplementary
Figure 7B).

(= Tagg[75]) and 53.5°C (= Tagg[50]), 75% and 50%,
respectively, of the β-F1-ATP synthase were aggregated
and removed from solution (Figure 6A). To investigate
drug concentration effects, we exposed cell lysates to
high (0.14~100 µM) (Figure 6B) or low concentrations
(0.00064~10 µM) of CADD522 (Supplementary Figure
8A) at a fixed heating temperature of Tagg(75) (= 58.2°C).
Band density of the β subunit increased as CADD522
concentration increased, suggesting that CADD522
stabilizes the protein upon heat challenge. Isothermal
dose-response curves showed that 50% of the β-F1-ATP
synthase remained stable with CADD522 at concentrations
(EC50) of 1.60 µM (experiment 1) and 1. 94 µM
(experiment 2). The Tagg(75) and Tagg(50) of the α-F1ATP synthase in lysates with vehicle control were similar
to those of the β-F1-ATP synthase (57.5°C and 52.0°C,
respectively) (Supplementary Figure 8B). CADD522

Interaction of α and β subunits of F1-ATP
synthase with CADD522
Cellular thermal shift assay (CETSA) is used
to assess drug: protein interactions based on the
drug-induced thermal stabilization of target proteins
(23828940, 29957028). Therefore, CETSA profiles a
characteristic fingerprint of target engagement along the
drug concentration axis [62, 63]. To delineate possible
engagement of CADD522 with the F1-ATP synthase, we
performed CETSA using specific antibodies to detect α- or
β-F1-ATP synthase subunits (α-F1 & β-F1). The thermal
melting profile of β-F1-ATP synthase in cell lysates with
vehicle control (0.1% DMSO) revealed that at 58.2°C

Figure 5: CADD522 inhibits mitochondrial ATP synthase activity. (A) Cells were treated with CADD522 for 24 hr in Complete

M or 4 hr in Galactose M, and ATP synthase activity (ATP Syn. Ac.) was determined in cell lysates (50 µl) using commercial kits according
to the manufacturer’s instruction. Absorbance was measured every 2 min (kinetic program) at 340 nm. Fold-differences were calculated
from the relative activity to the average of the vehicle control (0.1% DMSO, = 1). All determinations were in triplicate and repeated
twice (mean ± SD). *P < 0.05 compared to Control. (B) MCF7-RUNX2 and MCF7-Empty cells were treated with CADD522 for 24 hr in
Complete M, and mitochondrial ATP synthase activity was determined. *P < 0.05 compared to MCF7-Empty cells with vehicle treatment.
Experiments were performed in triplicate and repeated twice (mean ± SD). #P < 0.05 compared to MCF7-RUNX2 with vehicle treatment.
(C) A representative result of mitochondrial ATP synthase activity showing changes of Ratio over time. Ratio, relative absorbance to the
absorbance at 0 min. (D) Cell lysates (50 µg) isolated from MDA-231 and MDA-468 cells that were not treated with CADD522 were
directly incubated with CADD522 for 30 min, and the in vitro ATP synthase activity was determined. 0.05% DMSO was used as vehicle
control. Relative activity is expressed as changes in absorbance or Ratio per minute (∆Absorbance or ∆Ratio)/∆min.
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increased stability of the α-F1-ATP synthase upon heat
challenge (Supplementary Figure 8C). The EC50 of
CADD522 for the α-F1-ATP synthase was lower than 1
µM (< 0.14 µM). These results indicate that CADD522
may interact with both α- and β-F1-ATP synthase. To
confirm binding of CADD522 with F1-ATP synthase,
we performed differential scanning fluorimetry (DSF),
which monitors thermally-induced protein denaturation
[64]. For this, we used purified, recombinant α- or β-F1ATP synthase instead of crude lysates. Results showed
that CADD522 (25~200 µM) increased significantly
the melting temperature (Tm) of the purified α-F1-ATP
synthase (Supplementary Figure 8D, left), indicating that
CADD522 increased stability of the α subunit from heat
denaturation. However, no significant change in the Tm of
the recombinant β subunit was observed (Supplementary
Figure 8D, right).

cells and incubated for 6 hr to verify that CADD522
itself does not generate ROS in culture medium. We
determined the level of ROS using a commercial kit that
generates luminescent signals (Luc) proportional to H2O2
concentrations. As shown in Supplementary Figure 9A
(left), CADD522 did not significantly change H2O2 Luc
compared to the vehicle control.
Cells treated with CADD522 for 6 hr also did not
show a significant difference in the intensity of H2O2 Luc
compared to the vehicle control (Supplementary Figure
9A, middle), which was inconsistent with intracellular
ROS levels determined by CM-H2DCFDA (Figure 4A).
This may be because of differences in assay sensitivity.
However, CADD522 treatment for 18 hr significantly
increased the intensity of H2O2 Luc in MDA-231 and
MDA-468 cells, although the intensity was still low (<
100) (Supplementary Figure 9A, right).
Exogenous H2O2 (25 µM) generated a high level of
H2O2 Luc intensity in cell culture medium without cells,
and the intensity decreased in the presence of MDA-231
cells (Supplementary Figure 9B), which may be due to ROS
quenching by cellular antioxidants or catalase. However,
co-treatment with CADD522 and H2O2 for 6 hr further
increased the H2O2 Luc intensity in MDA-231 cells. Similar
results were observed in other BC cells co-treated with
CADD522 and H2O2 for 6 hr (Supplementary Figure 9C)

CADD522 further enhances ROS levels under
conditions of oxidative stress
ROS such as superoxide are converted to H2O2
within cells by superoxide dismutases [65, 66], and thus,
a change in H2O2 can reflect a general change in the ROS
level. Before evaluation of the effect of CADD522 on H2O2
levels, we first added CADD522 into Complete M without

Figure 6: Engagement of CADD522 with the mitochondrial F1-ATP synthase, β subunit. (A) Left: representative immunoblot

result of the β-F1-ATP synthase upon heat challenges. Multiple aliquots of cell lysate isolated from MDA-231 cells were heated in the
absence of CADD522 in temperature-gradient thermocycler (38~60°C) for 10 min. After cooling, the samples were centrifuged to separate
soluble fractions from precipitated proteins. Western blotting was performed for the β subunit using a specific antibody. DMSO, vehicle
control (0.1%); β-F1, β-F1-ATP synthase. Right: thermal melting profile of the β-F1-ATP synthase. Band density of the the β subunit was
quantified, normalized to loading (37°C), and analyzed for CETSA melting curves. Experiments were performed in three replicates (mean ±
SD) and repeated twice. (B) Left: representative immunoblot result of the β-F1-ATP synthase upon increasing concentrations of CADD522.
Right: dose-response target engagement of CADD522 in the β-F1-ATP synthase was performed at 58.2°C. Density of the the β subunit was
quantified, normalized to the vehicle control (0.1% DMSO), and analyzed for melting curves.
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and 24 hr (Figure 7A), and BC cells pre-treated with
CADD522 for 18 hr and then co-treated with H2O2 for
an additional 6 hr (Figure 7B). Notably, the H2O2 Luc
intensity increased as the concentration of exogenous H2O2
increased, which was further increased in the presence of
CADD522 (Figure 7A).
tert-Butyl hydroperoxide (t-BHP) is an organic
peroxide that induces oxidative damage and cell death
[67]. To circumvent ROS scavenging by serum, we
treated MCF7 and MDA-468 cells with CADD522
and/or t-BHP in serum-free medium (SFM) for 4 hr.
Intracellular ROS levels were increased significantly by
t-BHP alone (Figure 7C, Supplementary Figure 10A),
and considerably enhanced by combined CADD522 and
t-BHP treatment (Figure 7C). NAC (5 mM) robustly
reduced the augmented ROS levels in both cell lines. A
single treatment of CADD522 or t-BHP in SFM for 4
hr did not induce acute cell death in MCF7 and MDA468 cells (cell viability ≥ 70%), whereas the combined
treatment significantly decreased the viability (≤ 40%)
(Supplementary Figure 10B). NAC completely blocked
the combined treatment-induced cell death. Similar results
were observed in MCF7 or MDA-468 cells co-treated in
SFM for 24 hr, and in MDA-231 cells in Gal M (4 hr or 24
hr) (Supplementary Figure 10C).
Furthermore, when MDA-231 cells were grown in
Complete M for 24 hr, CADD522 had little effect on the

t-BHP-mediated cell growth inhibition (Supplementary
Figure 10D, middle). However, pre-treatment with
CADD522 for 24 hr before co-treatment significantly
increased the t-BHP-mediated cell growth inhibition
(Figure 7D), which was similar to that in cells treated
simultaneously for 72 hr (Supplementary Figure 10D,
right). Specifically, when MDA-231 cells were treated
concomitantly for 72 hr, the cell growth at 10 µM t-BHP
was 72.34 ± 4.25% in the vehicle control and 47.26 ±
6.28% in CADD522-treated cells. When cells were pretreated with CADD522 for 24 hr and consecutively cotreated with t-BHP for additional 24 hr, the cell growth at
10 µM t-BHP was 74.43 ± 9.02% in vehicle control and
47.18 ± 4.41% in CADD522 treatment.
Menadione (Vitamin K3, a precursor of Vitamin
K) is known to act as an anticancer agent in BC via
the mitochondria-mediated apoptotic pathway [68,
69]. Menadione induces ROS and rapidly lowers ATP
in MCF7 cells [68] and MDA-231 cells [70] through
intracellular redox cycling [70]. The IC50 (50% inhibitory
concentration) of Menadione in MCF7 and MDA-231
cells was reported to be 15 µM and 9 µM, respectively
[68, 70]. To evaluate if Menadione potentiates the
antiproliferative effects of CADD522 on BC cells, we
treated MCF7 and MDA-231 cells with Menadione
at a sublethal concentration (5 µM) in the presence or
absence of CADD522 (0~100 µM) for 72 hr. CADD522

Figure 7: Enhanced ROS levels in the presence of ROS generating agents. (A) Cells in Complete M were treated with

CADD522 (50 µM) in the presence of increasing concentration of H2O2 (0~100 µM) for 24 hr. The H2O2 Luc intensity was determined
as described in Materials and Methods. Note, The H2O2 Luc intensity indicates Values at Y-axis × 1,000. Experiments were performed
in triplicate and repeated twice (mean ± SD). *P < 0.05 compared to Control with no H2O2 treatment; #P < 0.05 compared to Control at
indicated H2O2 concentrations. (B) B cells were treated with CADD522 for 18 hr, and then coincubated with H2O2 for additional 6 hr. *P
< 0.05 compared to Control. (C) Intracellular ROS levels were determined in MCF7 and MDA-468 cells after cells were treated with
CADD522 and/or t-BHP for 4 hr in SFM. NAC (5 mM) was pretreated for 1 hr and further treated with CADD522 and t-BHP. Data are
presented as the relative value to Control (Fold). Experiments were done in four replicates and repeated twice (mean ± SD). *P < 0.05
compared to Control; **P < 0.001 compared to t-BHP alone; #P < 0.001 compared to CADD522 + t-BHP. (D) MDA-231 or MDA-468
cells were pretreated with CADD522 for 24 hr and further treated with t-BHP for 24 hr in the presence of CADD522. Cell growth was
determined by crystal violet staining. *P < 0.05 compared to no treatment; #P < 0.05 compared to Control at indicated t-BHP concentrations.
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alone exerted higher growth inhibition in MCF7 cells
than MDA-231 cells as reported [52], but MDA- 231
cells showed greater sensitivity to Menadione (57.82 ±
3.34%) than MCF7 cells (78.22 ± 3.50%) (Supplementary
Figure 10E). In the presence of CADD522, the sensitivity
of MDA-231 and MCF7 cells to Menadione increased
significantly, which was more discernible in MDA-231
cells than in MCF-7 cells. The growth of MDA-231 cells
was 31.61 ± 0.90% and that of MCF7 cells was 47.45 ±
3.79% in the presence of 50 µM CADD522. These data
support the conclusion that CADD522, through its ability
to elevate cellular ROS, is more effective at inhibiting
proliferation when additional ROS-generating systems
are provided.

and MCF7 cells. RUNX2 KD significantly increased the
level of PGC-1α, the master regulator of mitochondrial
biogenesis, but had no effects on the levels of nuclear
genes that regulate mitochondrial DNA transcription
and replication (Supplementary Figure 12E). On the
contrary, CADD522 significantly inhibited mRNA levels
of the majority of mitochondrial biogenesis-related genes
examined (Supplementary Figure 12F). Notably, the
expression level of PGC-1α mRNA in MCF7 cells was
almost completely suppressed by CADD522.

DISCUSSION
Some BC cells expressing RUNX2 exhibit altered
metabolic requirements, with reduced mitochondrial
respiration and increased glycolysis [52, 54]. Under
conditions where cellular ATP production is dependent
on mitochondrial OXPHOS (Pyruvate M or Galactose
M), ATP levels were lower in T47D-RUNX2 and MCF7RUNX2 cells compared to their Empty controls (Figure
3B and 3C). However, in Serum-Free Glucose M in which
mitochondrial ATP production was suppressed, ATP levels
increased slightly but significantly in ectopic RUNX2expressing cells (Supplementary Figure 4B, left), which
may be due to RUNX2-mediated increases in glycolysis
that result in increased ATP synthesis [52]. In complete
M, ATP levels did not change (Supplementary Figure
4B, right). The ATP synthase activity also decreased in
ectopic RUNX2-expressing cells compared to their Empty
controls (Figure 5B and 5C, Supplementary Figure 6A and
6B, Supplementary Table 2).
Our results identify CADD522 as a novel OXPHOS
inhibitor. The maximal respiratory capacity (MRC) and the
reserve capacity (RC) between ectopic RUNX2-expressing
cells and their Empty controls were not different
(Supplementary Figure 2E), but CADD522-mediated
inhibition of MRC and RC was higher in MCF7-RUNX2
cells than -Empty cells. These results suggest that RUNX2
might render BC cells more sensitive to CADD522. In
addition, inhibition of OCR with CADD522 treatment
was observed in MCF7 and T47D cells expressing either
ectopic RUNX2 protein or low levels of baseline RUNX2.
Decreased ATP levels were also observed in several BC
cell lines regardless of their RUNX2 status. Moreover,
intracellular and mitochondrial ROS levels increased in
CADD522-treated ectopic RUNX2-expressing T47D and
MCF7 cells (Supplementary Figure 5A and 5B) as well
as Hs578t cells with RUNX2 KD. These findings suggest
that the inhibitory effects of CADD522 on mitochondria
are RUNX2-independent.
Recent findings indicate that glycolysis and
mitochondrial OXPHOS cooperate under hypoxic and
nutrient-deprived selective pressures for cancer cell
growth. Under poorly perfused conditions, stem-like
cancer cells that rely on mitochondrial OXPHOS for their
survival exhibit drug resistance and increased metastatic

NAC attenuates the inhibitory effect of
CADD522 on BC cells growth
Pre-treatment of tumor cells with NAC, a general
ROS scavenger has been shown to provide protection
against the cytotoxicity of intracellular oxidants [58, 71]. It
is known that NAC can inhibit apoptosis [57] induced by
ROS. To address the role of ROS in CADD522-mediated
cell growth inhibition, we pre-treated BC cells with the
antioxidant NAC (5 mM, pH adjusted to neutrality) for
1 hr and then co-treated with CADD522 (0~500 µM) for
72 hr. NAC moderately but significantly attenuated the
CADD522-mediated cell growth inhibition (Figure 8A),
indicating that the inhibition is partially ROS-dependent.
In addition, NAC attenuated the CADD522-inhibited
tumorsphere formation of BC cells (Figure 8B). The
number of tumorspheres in cells treated with NAC in the
presence of CADD522 (NAC+CADD522) was similar to
that of the vehicle control, and importantly, the size and
shape of the tumorspheres in cells with NAC+CADD522
were not disrupted compared to the vehicle controls
without NAC (Supplementary Figure 11A). These results
indicate that CADD522 may exert its antitumor activity
at least through increased ROS levels and oxidative cell
damage.

Effect of CADD522 and RUNX2 KD on
expression of mitochondria-associated genes
To begin to explore the molecular mechanisms
that underlie how CADD522 or RUNX2 KD regulates
mitochondrial function, we first determined mRNA levels
of mitochondrial ETC and ATP synthase-encoding genes
by quantitative PCR analysis. Results show that, overall,
mRNA levels of these genes were not considerably
different between RUNX2 KD and NTC of Hs578t cells
or between CADD522-treated BC cells and the vehicle
control (Supplementary Figure 12A–12D). One exception
was the mRNA level of ATP5B (mitochondrial ATP
synthase F1 subunit beta, β-F1-ATP synthase), which
was markedly decreased by CADD522 in MDA-468
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potential [72]. Tumors that exist in nutrient-poor
environments are not highly proliferative but continue
to survive [73, 74] and, consequently, drugs that block
mitochondrial ATP production are predicted to induce
cell death in poorly perfused tumors. Tumors that show
a heavy dependence on OXPHOS for ATP production
(i.e., cancer stem cells) appear to be more sensitive to
drugs that limit mitochondrial ATP production since these
tumors do not compensate for reduced mitochondrial
ATP by increasing glycolytic ATP [42, 75–77]. Our
published data suggests that blockage of RUNX2 with
CADD522 inhibits glycolytic gene expression and
reduces glucose uptake [52]. Our current results show
that CADD522 decreased ATP production in cells under
conditions of limited glucose availability. Therefore, a
dual mechanistic basis for CADD522 action in BC may
be operative: RUNX2-mediated glycolysis inhibition
through suppression of Glut-1 gene expression [52] and
RUNX2-independent mitochondrial dysfunction through
repression of the activity of mitochondrial ATP synthase,
an alternative target for CADD522. Our data showing
that CADD522 and RUNX2 KD additively enhanced
inhibition of cell growth and colony forming ability of BC
cells (Supplementary Figure 11B and 11C) are supportive
evidence for this concept. Moreover, CADD522 can
synergize with therapies that diminish glycolysis
[20, 78]. Indeed, we observed that concurrent treatment
of CADD522 with 2-deoxyglucose (2-DG, an inhibitor of
glucose uptake) significantly increased the sensitivity of

MDA-231 cells to CADD522 (Supplementary Table 3).
Therefore, CADD522 demonstrates mechanistic proof of
concept by targeting mitochondrial ATP production alone
and in combination with glycolysis inhibitors.
Oligomycin inhibits ATP synthase activity because it
blocks proton (H+) translocation across the mitochondrial
inner membrane (Fo subunits). Rotation of the central
stalk against the surrounding α(3)β(3) subunits leads to
synthesis of ATP at three separate catalytic domains on
the β subunits [79, 80]. Our results are evidence that
CADD522 inhibits the ATP synthase activity in both cell
culture and cell-free lysates. The enzymatic assay used
in our study measures the F1-mediated ATP hydrolysis
activity (ATPase) as a surrogate for ATP synthase activity.
In this in vitro system, the FoF1-ATP synthase/ATPase
cannot use the mitochondrial protonmotive force (∆p)
for ATP synthesis as there is no membrane gradient after
immunocapture. The FoF1-ATP synthase thus does not
exhibit Fo-dependent, proton-coupled enzymatic activity.
Therefore, the F1 components of the ATP synthase are
likely potential CADD522 targets.
Indeed, we identified the α and β subunits of the
F1-ATP synthase as potential CADD522 interacting
proteins, supporting that both α and β subunits of the
F1-ATP synthase may be the actual CADD522 targets.
In both CETSA and DSF, which use total protein lysates
and purified individual proteins, respectively, CADD522
increased the protein stability of the α-F1-ATP synthase
against heat challenge. CADD522 increased the stability

Figure 8: NAC protects BC cells from CADD522-mediated growth inhibition. (A) Cells were pre-treated with NAC (5 mM,

pH adjusted to 7.2) for 1 hr, and cotreated with CADD522 (50 µM) for 72 hr. Cell growth was determined by crystal violet staining.
Data are presented as mean ± SD. Experiments were done in triplicate and repeated twice. *P < 0.05 compared to cells without NAC at
indicated CADD522 concentrations. Red line, 50% of cell growth. (B) Cells were plated in low attachment plates and cotreated with NAC
and CADD522 at the initial day of cell plating. Cells were incubated in suspension for 7 days. Data presented as mean ± SD. Experiments
were done in triplicate and repeated three times. *P < 0.05 compared to Control; #P < 0.05 compared to cells treated with CADD522 in the
absence of NAC.
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of the β-F1-ATP synthases in total lysates, whereas it
could not protect the purified, recombinant β-F1-ATP
synthases from heat denaturation. These results suggest
that CADD522 may directly interact with the α subunit,
but indirectly with β subunit. Many F1-ATP synthase
complex inhibitors interact with α and/or β subunits,
but most common interaction sites for these inhibitors
are known to be at the three α/β interface sites of the
F1 complex [43]. With recombinant F1-ATP synthase
components, we will validate in future studies whether
individual α and β subunits or the α/β interaction sites
are the relevant target, and how changes in α and/
or β stability could account for CADD522 effects
on mitochondrial ATP synthase activity [43]. Highly
specific, cutting edge drug-protein interaction assays
such as in vivo surface plasmon resonance (SPR) [81, 82]
will be helpful to uncover at which sites of the F1-ATP
synthase complex the functional binding occurs.
We reported that CADD522 promotes growth arrest
rather than apoptosis [52]. Apoptosis can be activated with
the use of compounds targeting key protein components
of the mitochondria such as Bcl-2 family proteins (prosurvival Bcl-2 and Bcl-xL and pro-apoptotic Bax and
Bak) [83]. The activity of OXPHOS is required for the
function of the proapoptotic protein Bax in yeast and
mammalian cells [42, 76, 84], which is dependent upon
the mitochondrial FoF1-ATP synthase proton pump [77].
Oligomycin A, an inhibitor of Fo-portion of the H+-ATP
synthase, halts the efficient execution of apoptosis [84, 85]
and suppresses TNF-induced apoptosis [86]. This suggests
that the activity of mitochondrial OXPHOS may be also
required for the overall apoptotic potential of BC cells
[86–89]. Therefore, the inhibitory effect of CADD522 on
the activity of the FoF1-ATP synthase could be one of the
reasons that CADD522 does not induce apoptotic changes
in BC cells [52].
Metformin lowers ATP production through inhibition
of mitochondrial ETC complex I [90]. Unlike metformin,
CADD522 diminished ATP levels through inhibition of
mitochondrial ATP synthase activity, without alteration
of complex I activity. Oligomycin inhibits mitochondrial
ATP synthase, which leads to changes in MMP (∆Ψm)
[79, 80]. However, CADD522 had no effect on changes
in the ratio of red to green fluorescence intensity of JC1, indicating little changes in the overall MMP (∆Ψm).
Targeting glycolysis and OXPHOS may lead to tissue
toxicity. However, our previous report demonstrated the
translational potential of CADD522 in in vitro and in
vivo tumor models without exhibiting in vitro and in vivo
toxicity [52]. Consistently, we did not observe significant
difference in cell viability between CADD522- and vehicletreated groups even when OCR and mitochondrial ATP
synthase activity were substantially inhibited. Therefore,
CADD522 may be uniquely different from other ATP
synthase inhibitors (such as oligomycin) that demonstrate
cytotoxicity and thus have no clinical application.
www.oncotarget.com

ROS production increases intracellular signaling and
tumorigenesis but also is deleterious to cells, depending
on the level and temporal expression of ROS, which may
be cell-type specific [91–93]. Similarly, antioxidants
have been shown to exhibit either pro-tumorigenic
or anti-tumorigenic activity [92, 94, 95]. Many drugs
target mitochondrial ATP synthase activity to lower ATP
levels and increase ROS within mitochondria [15, 22].
Benzodiazepine (Bz-423) [96] and oligomycin A [97, 98]
generate ROS from the respiratory chain by inhibition of
mitochondrial ATP synthase. Therefore, the suppressed
ATP synthase activity could contribute to the CADD522mediated increase of ROS formation in mitochondria.
CADD522 itself does not generate ROS but elevates ROS
in cell-based systems. A combination of CADD522 with
pro-oxidants that simultaneously increase ROS production
might be more useful to limit cancer cell growth. For
example, the combination of CADD522 with t-BHP
or menadione further enhanced ROS levels and growth
inhibition of MDA-231 cells. Our finding that N-acetyl
cysteine (NAC) attenuates the CADD522-inhibited
tumorsphere formation and cell proliferation in BC cells
indicate that ROS might be responsible for CADD522induced cell growth inhibition. Therefore, an increase in
ROS could provide a therapeutic advantage if CADD522
also inhibits glycolysis through RUNX2 inhibition [52].
Oxygen consumption rate (OCR) is a feature
of oxidative phosphorylation while the extracellular
acidification rate (ECAR) usually depends on glycolysis.
However, we did not observe a significant CADD522induced change in ECAR (mpH/min/µg protein) in any
cell lines tested. This may be due to buffering by HEPES
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
that we freshly added to Seahorse-certified medium
just before the assays. Addition of HEPES is known to
provide a buffering capacity to cell culture medium to
maintain physiological pH (7.2~7.6) despite changes in
CO2 concentration produced by respiration. When cells
are outside of a CO2 incubator to be processed on the
XF Extracellular Flux Analyzer, HEPES can work as a
“Good” buffer [99], thus maintaining neutral pH even
under conditions that increase ECAR with inhibition of
mitochondrial respiration.
The mitochondrial metabolic properties of cancer
cells are different from those of normal cells. In contrast
to normal cells, actively growing tumor cells exhibit
increased mitochondrial biogenesis and respiration for ATP
generation to meet energy demands and maintain survival
[100, 101]. Cancer stem cells are slow-growing cells that
harbor tumorigenic potential, self-renewal capabilities, and
intrinsic resistance to conventional and targeted therapies.
These cells are dependent on active mitochondria and
show increased oxygen consumption and ATP production
compared to more highly proliferating tumor cells [100,
102–104]. Therefore, inhibition of the mitochondrial
respiratory chain can be exploited to develop selective
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anticancer agents [26], since drugs targeting the ETC
can preferentially kill cancer cells [22]. We reported that
cell growth inhibition by CADD522 was significant in
13 different BC cells (TNBC, ER+, and HER2+), while
resistance of normal epithelial cells to CADD522 was
commonly observed [52]. Moreover, tumorspheres
organized from stem-like BC cells in suspension culture
(MCF7, MDA-231, MDA-468) were sensitive to
CADD522 treatment, but MCF10A cells that resemble
normal mammary epithelial cells (mammospheres) were
resistant [52]. Therefore, the higher sensitivity of BC cells
to CADD522 compared with normal epithelial cells might
be due to inhibitory effects of CADD522 on mitochondrial
OXPHOS and the increased ROS levels.
Mitochondrial biogenesis is the process via which
cells increase their individual mitochondrial mass [105].
RUNX2 KD in Hs578t cells increased the mitochondrial
mass, which was reflected by increased fluorescence
intensity of MitoTracker Green dye, and the mRNA level
of PGC-1α, indicating that RUNX2 might be involved
in regulation of mitochondrial biogenesis. CADD522
treatment for 12 hr did not change mRNA levels of
mitochondria-encoded genes (CytoB, MT-ATP6, MTCO2, etc.). However, CADD522 significantly decreased
the mRNA levels of nucleus-encoded mitochondrial
genes (PGC-1α, NRF-1, TFB2M, etc.) that activate the
expression of key metabolic genes regulating respiration
and mitochondrial DNA transcription and replication.
Therefore, we do not exclude the possibility that
CADD522 might interfere with mitochondrial dynamics
through regulation of nuclear genes whose products
target the processes that regulate mitochondrial content,
structure, and function. Further studies will be needed to
verify the precise effects of CADD522 on regulation of
mitochondrial biogenesis.
Moreover, expression of the catalytic subunit β-F1ATP synthase is tightly regulated by post-transcriptional
mechanisms that affect mRNA localization, stability and
translation [106–110]. The mRNA expression of ATP5B in
MCF7 and MDA-468 cells was substantially decreased by
CADD522 treatment. These results indicate that CADD522
might inhibit ATP synthase activity through regulation of
target gene expression levels and/or the activity of the
catalytic β subunit of the mitochondrial F1-ATP synthase. In
summary, our findings demonstrate that mitochondrial ATP
synthase inhibition may be a valid therapeutic approach and
that one mechanism that drives sensitivity of BC cells to
CADD522 is suppression of mitochondrial metabolism.

every 6 months. The cells for experiments were passaged
for less than 6 months. Cell lines were maintained in
DMEM/F12 (50:50) (BT474 and MDA-MB-468),
RPMI1640 (HCC1937, HCC1428, BT549, HCC70),
McCoy-5A (SKBr3), and DMEM (all other BC cancer
cells) supplemented with 10% FBS, 100 U/mL penicillin
and 100 mg/mL streptomycin. Establishment of T47D and
MCF7 cells stably expressing ectopic RUNX2 (T47DRUNX2 and MCF7-RUNX2), and their empty vector
controls (T47D-Empty and MCF7-Empty) were previously
described [52]. These cells were maintained under G418
(0.5~1 mg/ml). Hs578t cells with RUNX2 knockdown (KD)
(55.5), a negative clone of RUNX2 KD cells (54.5) and nontargeting control cells (NTC) were previously described [52,
54]. These cells were maintained under puromycin (1 μg/
ml). Notably for experiments, to avoid unwanted effects of
G418 or puromycin on mitochondria, these cells were plated
in cell culture medium without antibiotics and incubated
for a day, and then processed immediately or treated with
CADD522 in antibiotics-free medium. CADD522 was
purchased from ChemBridge Corporation (San Diego, CA).
Other drugs or agents were purchased from Sigma-Aldrich
(St Louis, MO, USA). Small-Interfering RNA (siRNA) pool
targeting RUNX2 and non-targeting control were purchased
from Dharmacon (Lafayette, CO, USA), and transfected into
cells using RNAiMAX Reagent (Invitrogen).

Mitochondrial oxygen consumption rate (OCR)
Dynamic changes in OCR, a result of oxidative
phosphorylation, were measured in live cells using the
Seahorse XF24 Extracellular Flux Analyzer (Agilent
Technologies, Santa Clara, CA, USA) according to
the manufacturer’s instructions. BC cells were seeded
(> 60,000 cells/well) in 24-well Seahorse plates and
incubated in complete growth medium. The following
day, cells were treated with CADD522, and incubated
up to 72 hr. At the time of OCR measurement, cells were
replenished with fresh Seahorse-XF DMEM (Cat. No.
102365-100) supplemented with 5 mM HEPES, 5 mM
glucose and 1% serum (pH-adjusted to 7.4 with Tris base
powder) in the absence of CADD522 and incubated for
one hour at 37°C in a non-CO2 incubator for stabilization
of temperature and pH. Cell plates were then loaded
onto the Seahorse Analyzer equipped for the sequential
addition of final concentrations of oligomycin (1 µg/ml),
carbonylcyanide-4-trifluoromethoxyphenylhydrazone
(FCCP, 1 µM), Pyruvate (10 mM) and Antimycin A (1
µM), with compounds that were freshly prepared just
before use. In some experiments, we added FCCP and/or
Pyruvate to two or three ports in the flux analyzer without
oligomycin to maximize and prolong the respiratory
reserve capacity measurement. At the end of the assay,
total protein content in individual wells was determined
and used for normalization of raw OCR values. OCR was
expressed as pMoles/min/µg protein.

MATERIALS AND METHODS
Cell lines and reagents
All BC cell lines were obtained from American Type
Culture Collection. Cells were subjected to routine cell
line quality examinations (e.g., morphology, Mycoplasma)
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To determine the acute OCR response in separate
experiments, T47D-RUNX2 and -Empty cells without
prior CADD522 treatment were replenished with Seahorse
medium an hour before the assay. At the time of the
assay, the assay buffer with 0.1% DMSO, oligomycin or
increasing concentrations of CADD522 (10~200 µM, final
concentration) was injected into port A, and the OCR was
measured at 37°C. Data are presented as OCR (%), the
percentage of the basal OCR at t = 12 min.
Mitochondrial respiration (OCR) was calculated
as maximal respiratory capacity (MRC) by subtracting
non-mitochondrial respiration (NM, OCR value at t =
63 min) from the FCCP rate; ATP production-linked
respiration (AP) by subtracting the oligomycin rate from
baseline cellular OCR; proton leak-linked respiration
(PL) by subtracting NM from the oligomycin rate; and
mitochondrial reserve capacity (RC) by subtracting
basal respiration (OCR value at t = 12 min) from MRC
(Supplementary Figure 2, right). Baseline cellular OCR
(BL) was calculated from basal respiration after subtracting
NM [111]. Percent (%) inhibition of the individual
parameters was calculated from the equation (A−B)/A ×
100; A, vehicle control; B, CADD522 treatment.

To detect mitochondrial superoxide levels, cells
were incubated with MitoSox Red (5 µM) (ThermoFisher
Scientific) in HBSS for 10 min and the fluorescence
was measured at 510/580 nm (Ex/Em). In parallel, the
cell viability of cells receiving the same treatments was
determined using the cell-permeant dye Calcein-AM (2
µg/ml) (ThermoFisher Scientific). The nonfluorescent
Calcein-AM is converted to green-fluorescent Calcein by
intracellular esterases in live cells, which is measured at
495/515 nm (Ex/Em). DCF or MitoSox Red fluorescence
was divided by Calcein green fluorescence to normalize
the ROS signal for cell viability.

Mitochondrial ATP synthase activity assay
Quantitative measurement of the activity of
mitochondrial ATP Synthase was performed using the
ATP Synthase Enzyme Activity Microplate Assay Kit
that is commercially available (Abcam, ab109714). After
cells were treated with CADD522 for the indicated period
of time in Complete M, cells were harvested and cell
lysates were extracted in buffers provided by the kit. ATP
synthase is localized in the mitochondria and the plasma
membrane of highly proliferating cells in eukaryotes [32,
50]. Therefore, homogenized samples (cell lysates) were
frozen, thawed and pelleted by centrifugation at ~16,000
rpm to fracture the plasma membranes and remove soluble
non-membrane associated proteins as per manufacturer’s
instruction. Pelleted samples were resuspended in the
supplied buffer. Enzymes in cell lysates (50 µl/well)
were immunocaptured within the wells of the microplate
and enzyme activity was determined by following the
reduction of substrates, coupled to the reduction of a
reporter dye to yield a colored reaction. Absorbance of
each well was measured every 2 min for up to 90 min in
a spectrophotometer purchased from BioTek Instruments
(SYNERGY/HTX multimode reader) (Winooski, VT,
USA) at a wavelength of 340 nm (kinetic program), and
the slope (= − Enzyme Activity) was calculated from the
linear range in each curve by the equation ([ΔAbsorbance
or ΔRatio]/Δmin/μg protein in 50 μl × 1000).
For the in vitro mitochondrial ATP Synthase activity
assay, 50 µg/50 µl of protein lysates isolated from MDA231 and MDA-468 cells were directly incubated in the
presence or absence of CADD522 (0~2 µM), and ATP
Synthase Activity was measured. Relative activity is
expressed as changes in absorbance or Ratio per minute
([ΔAbsorbance or ΔRatio]/Δmin/50 μg protein ×1000).
Ratio indicates relative value to the absorbance at 0 min.

ATP assay
Cells were treated with CADD522 for the indicated
time periods in pyruvate medium (Pyruvate M, 2 mM
pyruvate, no glucose, no glutamine, 5% serum), galactose
medium (Galactose M, 5 mM galactose, 1 mM pyruvate,
no glucose, 2 mM glutamine, 10% serum), normal cell
growth medium (Complete M, 25 mM glucose, 2 mM
glutamine, 1 mM pyruvate, 10% serum), or Serum-Free
Glucose M (25 mM glucose, no glutamine, no pyruvate,
0% serum), and ATP level was determined using
Luminescent ATP Detection Assay Kit purchased from
Abcam (Boston, MA) as per manufacturer’s instructions.
After addition of the assay mixture containing luciferin
and luciferase, luminescence was measured using a
Wallace microplate luminescence reader (Perkin Elmer,
Waltham, MA, USA).

Intracellular reactive oxygen species (ROS) and
mitochondrial superoxide levels
Cells in 96 well plates were treated with CADD522
in normal growth or serum-free medium (SFM). To detect
the intracellular formation of ROS, cells were incubated
with a fluorogenic dye 2′,7′-dichlorofluorescein diacetate
(CM-H2DCFDA, 25 µM) (ThermoFisher Scientific) for
1 hr. This dye produces the highly fluorescent product
2′,7′-dichlorofluorescein (DCF) upon reaction with ROS.
The fluorescence was measured at 488/535 nm (Ex/Em)
using a SYNERGY/HTX multimode reader (BioTek).
CM-H2DCFDA is more sensitive to oxidation by
hydrogen peroxide (H2O2) than superoxide [112].
www.oncotarget.com

Mitochondrial membrane potential (MMP)
(∆Ψm)
The changes in MMP were evaluated using a
cationic fluorescent indicator (JC-1; Molecular Probes,
Eugene, OR, USA), which aggregates in polarized
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Cellular thermal shift assay (CETSA)

mitochondria (red fluorescence), indicating high or normal
MMP and remains in monomeric form in the cytoplasm
when mitochondria are depolarized (green fluorescence),
indicated low MMP. Cells in 96 well plates were incubated
in the growth medium containing 1 mg/mL JC-1 dye for
30 minutes at 37°C, and fluorescence was acquired at
488/525 nm (ex/em) for JC-1 monomers and 488/590 nm
(ex/em) for J-aggregates using a fluorescence microplate
reader (BioTek). MMP (∆Ψm) was expressed as the ratio
of red to green fluorescence intensity. JC-1 aggregation
is a survival marker and JC-1 monomer is a cell death
indicator.
Alternatively, we assessed the MMP using
tetramethylrhodamine methyl ester (TMRM), a cellpermeant, cationic, red fluorescent dye that accumulates
in active (healthy and functioning) mitochondria with
intact membrane potentials. Upon loss of the MMP,
TMRM accumulation ceases and the signal disappears.
Cells were incubated with TMRM (50 µM) for 10 min and
fluorescence intensity was measured at 561/590 nm (ex/
em) in a microplate reader (BioTek). Carbonylcyanide-3chlorophenylhydrazone (CCCP, 50 µM), a mitochondrial
uncoupler, was used as a positive control for the MMP
reduction.

CETSA [62, 63] was performed with MDA-MB-231
cells cultured in DMEM medium supplemented with 10%
FBS. For an initial determination of the melting profile
of α- or β-F1-ATP synthase subunits (α-F1 and β-F1),
fresh cell lysate prepared in non-denaturing buffer was
dispensed into a 96-well PCR plate in the above medium
(approx. 6,000 cells/50 µl/well), and then was subjected to
temperature gradient (38~60°C) for 10 min. Subsequently,
centrifugation was performed at 14.000 rpm to sediment
the unstable protein content. Supernatant was collected
and SDS-PAGE gel was run, and immunoblot analysis was
performed for α-F1 and β-F1 using corresponding primary
antibodies. Band intensity was quantified on C-Digit Blot
Scanner (LI-COR Biosciences, Lincoln, NE, USA), and
subsequently Tagg(50) and Tagg(75) values (temperatures at
which 50% and 75% of the initial protein was reduced,
respectively) were calculated for each protein. In a
subsequent run, fresh lysates of MDA-MB-231 cells were
treated at various doses of CADD522 and vehicle control
(0.1% DMSO) for 1 hr. Samples were then subjected to
heat shock at Tagg(75) for 10 min, and unstable protein
was removed by centrifugation step. Following an
immunoblotting step, bands of stable target proteins were
quantified, normalized to loading control and plotted using
GraphPad Prism software. EC50 values of CADD522 with
each target protein were calculated.

Measurement of mitochondrial mass
Mitochondrial mass was determined with the
MitoTracker Green FM (Life Technologies) dye that
is non-fluorescent in aqueous solutions, but becomes
fluorescent upon accumulating in the mitochondrial lipid
environment regardless of membrane potential [113]. Cells
plated in 96 well plates were treated with CADD522 in
phenol red–free growth medium for 24 hr. Cells were
washed with HBSS, and then incubated with Mitotracker
Green as per manufacturer’s protocol. Green fluorescence
was determined at 490/516 nm (ex/em) in a fluorescence
microplate reader (BioTek).

Differential scanning fluorimetry (DSF)
Recombinant human mitochondrial ATP synthase
subunit α (α-F1-ATP synthase) and β (β-F1-ATP synthase)
were purchased from CusaBio (Houston, TX, USA). Binding
of CADD522 to α or β subunit was examined experimentally
using DSF, which evaluates changes in the target protein
melting temperature (Tm) due to interactions with the test
compound [64, 114, 115]. SYPRO orange (Thermo Fisher
Scientific) diluted 1:1000 in 10 mM HEPES, 150 mM NaCl
(pH 7.5), and 1.5 µM recombinant proteins were added to
96-well PCR plates. Then 0 to 200 µM CADD522 dissolved
in DMSO (1% final DMSO concentration) was added, the
plates were mixed, sealed, centrifuged at 1,000 rpm for 1
min, and melting curve analysis was performed using an
Applied Biosystems StepOne real-time PCR instrument. The
midpoint was determined from the first derivative curve,
and the corresponding temperature (Tm) was taken from the
midpoint.

Complex I (NADH dehydrogenase) activity
assays
Quantitative measurement of Complex I activity
was performed with a commercially available Complex
I Enzyme Activity Microplate Assay Kit (Abcam,
ab109721) as per manufacturer’s instruction. Cell
conditions for measuring Complex I activity were the
same as described for measuring the mitochondrial
ATP synthase activity. The activity was determined by
measuring the oxidation of NADH to NAD+ with the
simultaneous reduction of a dye (increased absorbance at
450 nm) for 30~60 min. Protein concentration was used to
normalize activity (∆Absorbance /∆min/µg protein in 50
µl × 1000), which was linear between 10–400 µg protein.
Data are presented in arbitrary units (au).

www.oncotarget.com

Hydrogen peroxide (H2O2)-ROS levels
Hydrogen peroxide (H2O2)-ROS levels were
determined using a commercial kit (ROS-Glo™ H2O2 Assay
kit, Promega), a luminescence-based assay that measures
the level of H2O2 directly in cell culture. Luciferin and
recombinant Luciferase in the kit generate a luminescent
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signal that is proportional to H2O2 concentration. Cells
plated in 96 Black (or white) well plates and incubated in
10% DMEM (Complete M) were treated with CADD522
with or without H2O2 (25 µM) for 6~24 hr. After exposure to
H2O2, 50 µl of media samples were transferred to a separate
plate to combine with an equal volume of ROS-Glo™
Detection Solution, and the ROS-Glo™ H2O2 Assay was
performed as per manufacturer’s instruction (the non-lytic
assay). H2O2 substrate provided by the kit was exogenously
added for ROS generation.

parametrical tests. All statistical analyses were conducted
using STATA version 14 (STATA Inc., College Station, TX,
USA). P values less than 0.05 were considered significant.

Abbreviations
BC: Breast cancer; OCR: Oxygen consumption rate;
CADD: Computer-Assisted Drug Design; ROS: reactive
oxygen species; OXPHOS: oxidative phosphorylation;
PDH: pyruvate dehydrogenase; MMP: mitochondrial
membrane potential; KD: knockdown; NTC: non-targeting
control cells; MRC: maximal respiratory capacity; NM:
non-mitochondrial respiration; AP: ATP production-linked
respiration; BL: baseline cellular OCR; PL: proton leaklinked respiration; RC: mitochondrial reserve capacity;
SFM: serum-free medium; CETSA: Cellular thermal shift
assay; DSF: Differential scanning fluorimetry; ATP5A:
mitochondrial ATP synthase subunit alpha (α-F1-ATP
synthase); ATP5B: mitochondrial ATP synthase subunit
beta (β-F1-ATP synthase); NAC: N-acetyl-l-cysteine.

Cell growth and survival assay
Cell growth was determined by crystal violet
staining. Cells were plated on 96-well (30,000 cells/well)
or 24-well plates (50,000 cells/well). After CADD522
treatment, cells were incubated for 24~72 hr. Cells were
stained with crystal violet (0.5% in methanol: acetic acid =
3:1) and washed with PBS. Crystal violet was solubilized
in DMSO and measured in a microplate reader at 592 nm.
For tumorsphere growth, single cell suspensions (100,000
cells/well) were plated in 6-well ultra-low attachment
plates (Corning) with 5 ml of DMEM supplemented with
10% serum. CADD522 (50 µM) was added at the day of
the plating or 4 days after plating. Tumorspheres were
photographed and counted at the final day of the assay
(day 7). Spheres were counted from 9 fields per well
and averaged from triplicate. For clonogenic survival
determination, cells were plated on 6-well plates (200
~500 cells/well). After CADD522 (50 µM) treatment, cells
were incubated for 2~3 weeks without changing media.
Colonies were fixed in Methanol-Acetic Acid solution
(3:1) and stained with crystal violet (0.5%). After washing,
colonies were photographed and counted.
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